Developments in the rat adjuvant arthritis model and its use in therapeutic evaluation of novel non-invasive treatment by SOD in Transfersomes.

The aim of this study was firstly to refine a rat model of arthritis, the adjuvant arthritis (AA) model, by studying the time course of the disease, introducing new evaluation methods such as haematological and biochemical parameters in order to identify the main stages of the disease. An optimisation of treatment schedule and evaluation criteria was developed. This refinement provided novel non-invasive anti-inflammatory treatment of the AA with SOD by using mixed lipid vesicles specially developed for transdermal delivery, Transfersomes (Tfs), this being the second major aim. The time course of AA includes a first stage: 1 day after the disease induction, the induced paw volume more than doubled and the paw circumference increased by approx. 50%. Two weeks later, another stage occurred where the disease shifted from the local arthritis form towards polyarthritis: an additional increase of volume and circumference of the induced and non-induced paws, occurred. The animals also started to loose weight around day 14 after the disease induction. Radiographic observable lesions increased correspondingly. Treatment of animals, started at day 1 after induction, by epicutaneous application of SOD-Tfs showed that 1 mg SOD/kg body weight is more efficient than 0.66 mg SOD /kg body weight. As a positive control, SOD liposomes intravenously injected were used for comparison and confirmed the biological efficiency of epicutaneously applied SOD in Tfs. SOD solution and empty Tfs epicutaneously applied exerted no effect. In addition, epicutaneous application of SOD-Tfs used prophylactically was able to suppress the induced rat paw oedema. Radiographic images showed less joint lesions in SOD-Tfs treated animals in comparison with control and placebo treated rats. It was shown for the first time that SOD incorporated into Tfs and applied onto a skin area not necessarily close to the inflamed tissue is able to promote non-invasive treatment of induced arthritis.

[1]  M. Cruz,et al.  The effect of cholate on solubilisation and permeability of simple and protein-loaded phosphatidylcholine/sodium cholate mixed aggregates designed to mediate transdermal delivery of macromolecules. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[2]  C. Pearson,et al.  Studies of polyarthritis and other lesions induced in rats by injection of mycobacterial adjuvant. I. General clinical and pathologic characteristics and some modifying factors , 1959 .

[3]  A. Schätzlein,et al.  Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. , 2002, Biochimica et biophysica acta.

[4]  A. Schätzlein,et al.  The skin: a pathway for systemic treatment with patches and lipid-based agent carriers , 1996 .

[5]  B. Newbould,et al.  CHEMOTHERAPY OF ARTHRITIS INDUCED IN RATS BY MYCOBACTERIAL ADJUVANT. , 1963, British journal of pharmacology and chemotherapy.

[6]  S. Luell,et al.  Therapeutic administration of a selective inhibitor of nitric oxide synthase does not ameliorate the chronic inflammation and tissue damage associated with adjuvant-induced arthritis in rats. , 1998, The Journal of pharmacology and experimental therapeutics.

[7]  Fredrik Johansson,et al.  Mechanisms for absorption enhancement of inhaled insulin by sodium taurocholate. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  W. Wąsowicz,et al.  Trace element status and inflammation parameters during chronic indomethacin treatment in adjuvant arthritic rats , 2007, Biological Trace Element Research.

[9]  G. Cevc.  Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. , 1996, Critical reviews in therapeutic drug carrier systems.

[10]  D. Crommelin,et al.  Superoxide dismutase entrapped in long-circulating liposomes: formulation design and therapeutic activity in rat adjuvant arthritis. , 2002, Biochimica et biophysica acta.

[11]  S. Cuzzocrea,et al.  Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. , 2001, Pharmacological reviews.

[12]  V. Strand,et al.  Low dose glucocorticoids in early rheumatoid arthritis. , 2003, Clinical and experimental rheumatology.

[13]  D. Kvam,et al.  Differences in the Severity of Adjuvant Arthritis in Four Strains of Rats , 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[14]  Problem solving in real time. , 1990, Hospital practice.

[15]  À. Franch,et al.  Adjuvant arthritis pretreatment with type II collagen and Mycobacterium butyricum. , 1992, Immunobiology.

[16]  H. Katinger,et al.  Topically applied liposome encapsulated superoxide dismutase reduces postburn wound size and edema formation. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  M. Cruz,et al.  Design and characterization of enzymosomes with surface-exposed superoxide dismutase. , 2003, Biochimica et biophysica acta.

[18]  P. Vanelle,et al.  Clinical Pharmacokinetics and Delivery of Bovine Superoxide Dismutase , 1995, Clinical pharmacokinetics.

[19]  J. Morais,et al.  Liposomal formulations of Cu,Zn-superoxide dismutase: physico-chemical characterization and activity assessment in an inflammation model , 1997 .

[20]  J. Stuart,et al.  EFFICACY OF TESTS USED TO MONITOR RHEUMATOID ARTHRITIS , 1989, The Lancet.

[21]  L. Laine,et al.  Guidelines for the appropriate use of non‐steroidal anti‐inflammatory drugs, cyclo‐oxygenase‐2‐specific inhibitors and proton pump inhibitors in patients requiring chronic anti‐inflammatory therapy , 2004, Alimentary pharmacology & therapeutics.

[22]  P. Caliceti,et al.  Anti-inflammatory activity of monomethoxypolyethylene glycol superoxide dismutase on adjuvant arthritis in rats. , 1991, Pharmacological research.

[23]  I. Otterness.  The value of C-reactive protein measurement in rheumatoid arthritis. , 1994, Seminars in arthritis and rheumatism.

[24]  T. Langenegger,et al.  Drug treatment for rheumatoid arthritis. , 1999, Clinical orthopaedics and related research.

[25]  E. Brahn.  Animal models of rheumatoid arthritis. Clues to etiology and treatment. , 1991, Clinical orthopaedics and related research.

[26]  D. Apple,et al.  Evaluation of preoperative and postoperative prophylactic regimens for prevention and treatment of diffuse lamellar keratitis , 2004, Journal of cataract and refractive surgery.

[27]  R. Greenwald.  Animal models for evaluation of arthritis drugs. , 1991, Methods and findings in experimental and clinical pharmacology.

[28]  Gregory Gregoriadis,et al.  Dehydration-Rehydration Vesicles: A Simple Method for High Yield Drug Entrapment in Liposomes , 1984, Bio/Technology.

[29]  A. Schätzlein,et al.  Transfersomes-mediated transepidermal delivery improves the regio-specificity and biological activity of corticosteroids in vivo , 1997 .

[30]  K. Puget,et al.  Anti-inflammatory activity of superoxide dismutases: comparison of enzymes from different sources in different models in rats: mechanism of action. , 1986, Free radical research communications.

[31]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[32]  I. Kushner,et al.  C-reactive protein and the acute-phase response. , 1990, Hospital practice.

[33]  T. Motawi,et al.  Effect of vitamin C administration in modulating some biochemical changes in arthritic rats. , 1992, Pharmacological research.

[34]  M. Cruz,et al.  Biochemical changes in arthritic rats: dehydroascorbic and ascorbic acid levels. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[35]  W. Oyen,et al.  Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. II. In vivo fate in a rat model of adjuvant arthritis. , 1999, Biochimica et biophysica acta.

[36]  W. Oyen,et al.  Subcutaneous Administration of Superoxide Dismutase Entrapped in Long Circulating Liposomes: In Vivo Fate and Therapeutic Activity in an Inflammation Model , 2000, Pharmaceutical Research.

[37]  E. Mazzon,et al.  Cloricromene, a coumarine derivative, protects against collagen‐induced arthritis in Lewis rats , 2000, British journal of pharmacology.

[38]  A. Vaille,et al.  Anti-inflammatory activity of various superoxide dismutases on polyarthritis in the Lewis rat. , 1990, Biochemical pharmacology.

[39]  G. Cevc,et al.  Biological activity and characteristics of triamcinolone-acetonide formulated with the self-regulating drug carriers, Transfersomes. , 2003, Biochimica et biophysica acta.

[40]  J. Bishop,et al.  A simple inflammation model that distinguishes between the actions of anti-inflammatory and anti-rheumatic drugs , 1998, Inflammation Research.

[41]  B. Ames,et al.  Age‐associated decline in ascorbic acid concentration, recycling, and biosynthesis in rat hepatocytes—reversal with (R)‐α‐lipoic acid supplementation , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  G. Cevc.  Transdermal Drug Delivery of Insulin with Ultradeformable Carriers , 2003, Clinical pharmacokinetics.

[43]  D. Y. Graham.  ‘Guidelines’ or marketing for non‐steroidal anti‐inflammatory drug and proton pump inhibitor use? , 2004, Alimentary Pharmacology and Therapeutics.

[44]  M. Currie,et al.  Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. , 1995, European journal of pharmacology.

[45]  E. Sigg,et al.  MYCOBACTERIAL ADJUVANT PERIARTHRITIS IN RODENTS AND ITS MODIFICATION BY ANTIINFLAMMATORY AGENTS , 1966 .

[46]  Andreas G. Schätzlein,et al.  Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. , 1998, Biochimica et biophysica acta.